Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models

24 Dec 2024

Abstract excerpt

Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogene in lung adenocarcinoma, with G12C and G12V being the most predominant forms. Recent breakthroughs in KRASG12C inhibitors have transformed the clinical management of patients with the G12C mutation and advanced our understanding of the function of this mutation. However, little is known about the targeted disruption of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39718828
DOI: 10.1172/jci174249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer modelsPMID 39718828Read ↗

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma.Semantic proximity Read ↗

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinomaSemantic proximity Read ↗

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.Semantic proximity Read ↗

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinomaSemantic proximity Read ↗

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinomaSemantic proximity Read ↗

Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.